Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (BIO-B) is currently trading at $304.15, with a 52-week range of $218.14 to $343.12. Reaching the $365 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Whether Bio-Rad Laboratories, Inc. can reach $365 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, BIO-B has delivered a -14.8% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the BIO-B Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Whether Bio-Rad Laboratories, Inc. (BIO-B) is worth buying at $304.15 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Bio-Rad Laboratories, Inc. trades at a Price-to-Earnings (P/E) ratio of 47.3x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.

Profitability & efficiency: Bio-Rad Laboratories, Inc. has a Return on Capital Employed (ROCE) of 2.2%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at 2.4%.

Financial health: The Debt-to-Equity ratio of 18.58 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: Analyst estimates are not currently available for BIO-B. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

Analyst price target data for Bio-Rad Laboratories, Inc. (BIO-B) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore BIO-B's financial ratios, historical returns, and fundamental data available on this page to form your own view.

Bio-Rad Laboratories, Inc. (BIO-B) currently has a Price-to-Earnings (P/E) ratio of 47.3x, meaning investors are paying $47.3 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:

Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 47.3x P/E is on the higher end, suggesting the market is pricing in continued strong earnings growth — any disappointment in future earnings could lead to a multiple contraction.

Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation. Bio-Rad Laboratories, Inc.'s ROCE of 2.2% suggests it has moderate capital returns.

Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of BIO-B's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.

Projecting Bio-Rad Laboratories, Inc. (BIO-B)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

Based on BIO-B's historical 5-year Compound Annual Growth Rate (CAGR) of -14.8%, if that rate of growth were to continue, the stock could reach approximately $188 by 2029 — up from its current price of $304.15. This projection assumes the historical CAGR holds, which depends on Bio-Rad Laboratories, Inc. sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the BIO-B Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.